Vaccine candidates against leishmania under current research
Introduction: The search for vaccines to prevent human leishmaniasis is an active field of investigation aimed to prevent the devastating effects of this family of diseases on human health. The design and commercialization of several vaccines against canine leishmaniasis is a hopeful advance toward...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-04-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2018.1459191 |
| _version_ | 1827813203977961472 |
|---|---|
| author | Salvador Iborra José Carlos Solana José María Requena Manuel Soto |
| author_facet | Salvador Iborra José Carlos Solana José María Requena Manuel Soto |
| author_sort | Salvador Iborra |
| collection | DOAJ |
| description | Introduction: The search for vaccines to prevent human leishmaniasis is an active field of investigation aimed to prevent the devastating effects of this family of diseases on human health. The design and commercialization of several vaccines against canine leishmaniasis is a hopeful advance toward the achievement of a human vaccine. Areas covered: This review includes a summary of the most relevant immunological aspects accompanying leishmaniasis in natural hosts as well as a description of the latest advances in the multiple strategies that are being followed to develop leishmanial prophylactic vaccines. We have combined citations of the latest specialized reviews with research articles presenting the most recent results. Expert commentary: Achieving safe, effective, durable and low-cost prophylactic vaccines against leishmaniasis is still a major challenge. These vaccines should control not only parasite progression, but also the accompanying pathology, which results from an imbalanced interaction between the infectious agent and the human host immune system. Different strategies for development of vaccines are currently under investigation. They range from the use of live non-pathogenic vectors to the employment of subunit vaccines combined with adjuvants and/or delivery systems inducing cell-mediated immunity. |
| first_indexed | 2024-03-11T23:29:26Z |
| format | Article |
| id | doaj.art-0d4d1476045145d38e73ab505baea050 |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T23:29:26Z |
| publishDate | 2018-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-0d4d1476045145d38e73ab505baea0502023-09-20T10:18:03ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952018-04-0117432333410.1080/14760584.2018.14591911459191Vaccine candidates against leishmania under current researchSalvador Iborra0José Carlos Solana1José María Requena2Manuel Soto3Immunobiology of Inflammation LaboratoryUniversidad Autónoma de MadridUniversidad Autónoma de MadridUniversidad Autónoma de MadridIntroduction: The search for vaccines to prevent human leishmaniasis is an active field of investigation aimed to prevent the devastating effects of this family of diseases on human health. The design and commercialization of several vaccines against canine leishmaniasis is a hopeful advance toward the achievement of a human vaccine. Areas covered: This review includes a summary of the most relevant immunological aspects accompanying leishmaniasis in natural hosts as well as a description of the latest advances in the multiple strategies that are being followed to develop leishmanial prophylactic vaccines. We have combined citations of the latest specialized reviews with research articles presenting the most recent results. Expert commentary: Achieving safe, effective, durable and low-cost prophylactic vaccines against leishmaniasis is still a major challenge. These vaccines should control not only parasite progression, but also the accompanying pathology, which results from an imbalanced interaction between the infectious agent and the human host immune system. Different strategies for development of vaccines are currently under investigation. They range from the use of live non-pathogenic vectors to the employment of subunit vaccines combined with adjuvants and/or delivery systems inducing cell-mediated immunity.http://dx.doi.org/10.1080/14760584.2018.1459191leishmaniavaccinesexperimental modelsadjuvantimmune responseclinical trials |
| spellingShingle | Salvador Iborra José Carlos Solana José María Requena Manuel Soto Vaccine candidates against leishmania under current research Expert Review of Vaccines leishmania vaccines experimental models adjuvant immune response clinical trials |
| title | Vaccine candidates against leishmania under current research |
| title_full | Vaccine candidates against leishmania under current research |
| title_fullStr | Vaccine candidates against leishmania under current research |
| title_full_unstemmed | Vaccine candidates against leishmania under current research |
| title_short | Vaccine candidates against leishmania under current research |
| title_sort | vaccine candidates against leishmania under current research |
| topic | leishmania vaccines experimental models adjuvant immune response clinical trials |
| url | http://dx.doi.org/10.1080/14760584.2018.1459191 |
| work_keys_str_mv | AT salvadoriborra vaccinecandidatesagainstleishmaniaundercurrentresearch AT josecarlossolana vaccinecandidatesagainstleishmaniaundercurrentresearch AT josemariarequena vaccinecandidatesagainstleishmaniaundercurrentresearch AT manuelsoto vaccinecandidatesagainstleishmaniaundercurrentresearch |